Trial Profile
A Phase II, Single-Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2018
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 03 Aug 2018 Status changed to discontinued early due to lack of accrual.
- 07 Feb 2017 Status changed from recruiting to completed.
- 23 Jun 2009 New trial record